Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.
The partnership leverages Salipro Biotech’s proprietary Salipro® platform technology, which stabilises membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro®-technology to identify potential therapeutic candidates.
Under the terms of the agreement, Salipro Biotech will receive research payments, option payments and is eligible for downstream success-based milestone payments based on developmental results generated by Boehringer Ingelheim under this collaboration.
“We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.”
